On September 12th, Gelunhui reported that Beijing Beilu Pharmaceutical (300016.SZ) received a specific research on September 11, 2024, regarding the "company's production capacity utilization." The company stated that the current production capacity utilization of Beijing Beilu Pharmaceutical can meet the business development needs for the next two to three years. In order to meet the demands of future business development, the company is actively expanding its production capacity. As an important holding subsidiary of the company, Haichang Pharmaceutical added 50 tons of iodine alcohol API capacity in 2023, and increased the production line of 100 tons of iodine mefupol API. Currently, it has a total of 1,000 tons of iodine contrast agent projects and production lines for a total of 7 varieties.

At the same time, the company's production capacity construction work is progressing simultaneously. The high-end intelligent injection workshop construction project, and the preparations for the pre-commissioning of the Cangzhou Phase III API production project are about to be completed. The construction of the production base in Bozhou is also progressing comprehensively. After the completion of the above work, the company's production capacity will be elevated to a new level.